Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
Aglycosylated Fc-containing polypeptides with cysteine substitutions
US9546203B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9546203-B2 |
| Application number | US-201414209914-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 13, 2014 |
| Priority date | Mar 14, 2013 |
| Publication date | Jan 17, 2017 |
| Grant date | Jan 17, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
First claim
Opening claim text (preview).
What is claimed is: 1. A polypeptide comprising an Fc region of a human IgGl antibody wherein said Fc region comprises a N297G mutation, using EU numbering scheme, one or more substitutions of the amino acid sequence set forth in SEQ ID NO: 3 at position V259, A287, R292, V302, L306, V323, or I332, using EU numbering scheme, with a cysteine amino acid residue, and said Fc region of a human IgGl comprises at least 95% identity to the amino acid sequence set forth in SEQ ID NO:3. 2. The polypeptide of claim 1 , wherein said Fc region comprises a A287C and L306C substitution, using EU numbering scheme, within the amino acid sequence set forth in SEQ ID NO:3. 3. The polypeptide of claim 1 , wherein said Fc region comprises a V259C and L306C substitution, using EU numbering scheme, within the amino acid sequence set forth in SEQ ID NO:3. 4. The polypeptide of claim 1 , wherein said Fc region comprises a R292C and V302C substitution, using EU numbering scheme, within the amino acid sequence set forth in SEQ ID NO:3. 5. The polypeptide of claim 1 , wherein said Fc region comprises a V323C and I332C substitution, using EU numbering scheme, within the amino acid sequence set forth in SEQ ID NO:3.
Assignees
Inventors
Classifications
Drugs for immunological or allergic disorders · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunomodulators · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9546203B2 cover?
- Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylat…
- Who is the assignee on this patent?
- Amgen Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K14/55. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).